Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis

BACKGROUND: Evaluation of costs and short-term cost-effectiveness of infliximab plus methotrexate (IFX + MTX); triple therapy of hydroxychloquine, sulphasalazine, and methotrexate (TRIPLE); or methotrexate monotherapy (MTX) in patients with new-onset polyarticular juvenile idiopathic arthritis (JIA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarkiainen, Maarit, Tynjälä, Pirjo, Vähäsalo, Paula, Aalto, Kristiina, Kröger, Liisa, Rebane, Katariina, Lahdenne, Pekka, Martikainen, Janne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670564/
https://www.ncbi.nlm.nih.gov/pubmed/36384562
http://dx.doi.org/10.1186/s12969-022-00748-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670564/
https://www.ncbi.nlm.nih.gov/pubmed/36384562
http://dx.doi.org/10.1186/s12969-022-00748-w

Ejemplares similares